Johnson & Johnson has just undergone its most significant transformation in decades. In 2023, the consumer health segment was ...

While acknowledging that Keytruda’s loss of exclusivity in 2028 represents the largest patent cliff in biopharma, BMO said it is now confident Merck can replace about 90% of peak Keytruda sales over ...

Thursday, December 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA ...

Antipodes Healthcare Portfolio Manager, Nick Cameron highlighted why Antipodes believes Merck & Co is entering 2026 at an ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

New Jersey now has more than 80 data centers, many clustered near Manhattan. Critics worry about their potential to hike ...

Some of the best opportunities heading into 2026 may come from stocks that already hold strong market positions but are ...

The IRA requires health plans serving the Part D market to cover all negotiated drugs, and it has been predicted that CMS will use the annual formulary review process to ensure that plans cover all ...

Investors with a lot of money to spend have taken a bullish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Halozyme HALO3.44%increase; green up pointing triangle was granted a preliminary injunction that would prevent Merck MRK 0.40%increase; green up pointing triangle & Co. from distributing a formulation ...

For the better part of a year, Merck & Co. and Halozyme have been locked in an intellectual property disagreement over the the pharma giant's new, under-the-skin version of cancer megablockbuster ...

The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with ...